These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 11552226)

  • 41. Docetaxel: new preparation. No first-line use in metastatic breast cancer.
    Prescrire Int; 2001 Dec; 10(56):178-9. PubMed ID: 11824441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recent progress in the clinical development of docetaxel (Taxotere).
    Hortobagyi GN
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial.
    Mattioli R; Lippe P; Massacesi C; Cappelletti C; Nacciarriti D; Bisonni R; Graziano F; Menichetti ET; Imperatori L; Testa E; Laici G; Balletra A; Silva RR
    Anticancer Res; 2004; 24(5B):3257-61. PubMed ID: 15510620
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
    Cassier PA; Chabaud S; Trillet-Lenoir V; Peaud PY; Tigaud JD; Cure H; Orfeuvre H; Salles B; Martin C; Jacquin JP; Agostini C; Guastalla JP; Pérol D; Bachelot T
    Breast Cancer Res Treat; 2008 May; 109(2):343-50. PubMed ID: 17611792
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
    Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
    Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolution in the treatment of advanced breast cancer.
    Crown J
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Special focus on cardiac toxicity of different sequences of adjuvant doxorubicin/docetaxel/CMF regimens combined with radiotherapy in breast cancer patients.
    Magné N; Castadot P; Chargari C; Di Leo A; Philippson C; Van Houtte P
    Radiother Oncol; 2009 Jan; 90(1):116-21. PubMed ID: 19013659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment for anthracycline-pretreated metastatic breast cancer.
    O'Shaughnessy J; Twelves C; Aapro M
    Oncologist; 2002; 7 Suppl 6():4-12. PubMed ID: 12454314
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integration of docetaxel into adjuvant breast cancer treatment regimens.
    Hortobagyi GN
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):27-33. PubMed ID: 12108895
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
    D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer.
    Eniu A; Palmieri FM; Perez EA
    Oncologist; 2005 Oct; 10(9):665-85. PubMed ID: 16249346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ongoing US cooperative group trials using taxanes in the adjuvant setting.
    Davidson NE
    Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S53-8. PubMed ID: 12435293
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
    Valero V; Hortobagyi GN
    J Clin Oncol; 2003 Mar; 21(6):959-62. PubMed ID: 12637456
    [No Abstract]   [Full Text] [Related]  

  • 55. Recently initiated studies: neoadjuvant treatments in the next century.
    Gradishar WJ
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):26-9. PubMed ID: 10203268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
    Nabholtz JM; Riva A
    Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S7-14. PubMed ID: 11970739
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
    Lluch A; Ojeda B; Colomer R; Barnadas A; Massuti B; Casado A; Angeles C; Maroto P
    Cancer; 2000 Dec; 89(11):2169-75. PubMed ID: 11147586
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival.
    Heys SD; Sarkar T; Hutcheon AW
    Breast Cancer Res Treat; 2005 Mar; 90(2):169-85. PubMed ID: 15803364
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
    Dang CT
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):427-36. PubMed ID: 16503859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Docetaxel in the treatment of breast cancer: an update on recent studies.
    Nabholtz JM; Reese DM; Lindsay MA; Riva A
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):28-34. PubMed ID: 12170449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.